Literature DB >> 3621161

Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213).

J M van Maanen, J de Vries, D Pappie, E van den Akker, V M Lafleur, J Retèl, J van der Greef, H M Pinedo.   

Abstract

The antitumor agent VP-16-213 is oxidatively O-demethylated by rat liver microsomes and purified rat liver microsomal cytochrome P-450. 3-Methylcholanthrene can quantitatively induce O-demethylation of VP-16-213. The Km and Vmax values for O-demethylation by noninduced, phenobarbital-, and 3-methylcholanthrene-induced rat liver microsomes were found to be 130, 600, and 160 microM and 8.5, 11.8, and 15.6 nmol H2CO/min X mg protein, respectively. Mass spectrometric comparison of the product of O-demethylation of VP-16-213 with the synthetic metabolite resulted in identification of the orthodihydroxy derivative. In studies on the biological activity of the orthodihydroxy derivative, it was found to inactivate single- and double-stranded phiX174 DNA, to bind to calf thymus DNA and to be highly toxic against chinese hamster ovary cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3621161

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

2.  Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.

Authors:  Huw D Thomas; David J Porter; Imke Bartelink; Joy R Nobbs; Michael Cole; Suzie Elliott; David R Newell; A Hilary Calvert; Martin Highley; Alan V Boddy
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 3.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.

Authors:  K T Kivistö; H K Kroemer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

5.  Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Suchandra Bhattacharjee; Michael G Espey; Ronald P Mason
Journal:  J Pharmacol Exp Ther       Date:  2013-09-18       Impact factor: 4.030

6.  Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate.

Authors:  H J Haisma; E Boven; M van Muijen; R De Vries; H M Pinedo
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

7.  Evidence that ubiquinone is a required intermediate for rhodoquinone biosynthesis in Rhodospirillum rubrum.

Authors:  Brian C Brajcich; Andrew L Iarocci; Lindsey A G Johnstone; Rory K Morgan; Zachary T Lonjers; Matthew J Hotchko; Jordan D Muhs; Amanda Kieffer; Bree J Reynolds; Sarah M Mandel; Beth N Marbois; Catherine F Clarke; Jennifer N Shepherd
Journal:  J Bacteriol       Date:  2009-11-20       Impact factor: 3.490

Review 8.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Antitumor agents. 126. Novel 4 beta-substituted anilino derivatives of 3',4'-O,O-didemethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase II.

Authors:  Z Q Wang; Y C Shen; H X Chen; J Y Chang; X Guo; Y C Cheng; K H Lee
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

10.  Stability of the i.v. and oral formulations of etoposide in solution.

Authors:  S P Joel; P I Clark; M L Slevin
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.